Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,988 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, Shinohara K, Hashimoto T, Hase R, Matono T, Kato H, Mawatari M, Hara H, Hamada Y, Saito S, Ohmagari N, Doi Y. Hayakawa K, et al. Among authors: kato h. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0051023. doi: 10.1128/aac.00510-23. Epub 2023 Sep 13. Antimicrob Agents Chemother. 2023. PMID: 37702483 Free PMC article.
Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae.
Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J, Doi A, Sekiya N, Nei T, Okinaka K, Kasahara K, Kurai H, Nagashima M, Miyoshi-Akiyama T, Kakuta R, Yano H, Ohmagari N. Hayakawa K, et al. Among authors: kato h. J Antimicrob Chemother. 2020 Mar 1;75(3):697-708. doi: 10.1093/jac/dkz501. J Antimicrob Chemother. 2020. PMID: 31789374
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. Doi Y, et al. Among authors: kato y, kato h. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958718 Free PMC article. Clinical Trial.
Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: kato h. Jpn J Radiol. 2022 Aug;40(8):800-813. doi: 10.1007/s11604-022-01270-5. Epub 2022 Apr 9. Jpn J Radiol. 2022. PMID: 35396667 Free PMC article. Clinical Trial.
Response to RMED-D-22-00,258.R1.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: kato h. Jpn J Radiol. 2022 Aug;40(8):860-861. doi: 10.1007/s11604-022-01308-8. Epub 2022 Jun 25. Jpn J Radiol. 2022. PMID: 35751793 Free PMC article. No abstract available.
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: kato h. Cell Rep. 2023 Dec 26;42(12):113580. doi: 10.1016/j.celrep.2023.113580. Epub 2023 Dec 15. Cell Rep. 2023. PMID: 38103202 Free article.
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Imai M, et al. Among authors: kato h. Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):e2106535118. doi: 10.1073/pnas.2106535118. Proc Natl Acad Sci U S A. 2021. PMID: 34140350 Free PMC article.
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Ueda A, Kato H, Oka H, Nishida Y, Nidaira Y, Asami T, Jinta T, Nakamura A, Oba K, Taniyama D, Yamamoto K, Tanaka K, Ueshima K, Fuwa T, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Arashiro T, et al. Among authors: kato y, kato h. Open Forum Infect Dis. 2023 May 3;10(6):ofad240. doi: 10.1093/ofid/ofad240. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37351451 Free PMC article.
Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan.
Oka K, Matsumoto A, Tetsuka N, Morioka H, Iguchi M, Ishiguro N, Nagamori T, Takahashi S, Saito N, Tokuda K, Igari H, Fujikura Y, Kato H, Kanai S, Kusama F, Iwasaki H, Furuhashi K, Baba H, Nagao M, Nakanishi M, Kasahara K, Kakeya H, Chikumi H, Ohge H, Azuma M, Tauchi H, Shimono N, Hamada Y, Takajo I, Nakata H, Kawamura H, Fujita J, Yagi T; Japan Infection Prevention and Control Conference for National and Public University Hospitals. Oka K, et al. Among authors: kato h. J Glob Antimicrob Resist. 2022 Jun;29:247-252. doi: 10.1016/j.jgar.2022.04.004. Epub 2022 Apr 13. J Glob Antimicrob Resist. 2022. PMID: 35429667 Free article.
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, Chubachi K, Yanagisawa N, Nagura Y, Kato Y, Ueda A, Numata A, Kato H, Ishii K, Ooki T, Oka H, Nishida Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Arashiro T, et al. Among authors: kato y, kato h. Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635. Clin Infect Dis. 2023. PMID: 35918782 Free PMC article.
8,988 results